Edition:
India

Spark Therapeutics Inc (ONCE.OQ)

ONCE.OQ on NASDAQ Stock Exchange Global Select Market

55.02USD
23 Feb 2018
Change (% chg)

$0.83 (+1.53%)
Prev Close
$54.19
Open
$54.86
Day's High
$55.12
Day's Low
$52.80
Volume
186,735
Avg. Vol
281,062
52-wk High
$91.75
52-wk Low
$41.06

Select another date:

Tue, Feb 20 2018

Spark licenses blindness gene therapy rights outside U.S. to Novartis

Spark Therapeutics Inc , whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, said on Wednesday that it had licensed rights to the drug outside the United States to Switzerland-based Novartis AG .

Spark licenses blindness gene therapy rights outside U.S. to Novartis

Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, said on Wednesday that it had licensed rights to the drug outside the United States to Switzerland-based Novartis AG.

UPDATE 1-Spark licenses blindness gene therapy rights outside U.S. to Novartis

Jan 24 Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, said on Wednesday that it had licensed rights to the drug outside the United States to Switzerland-based Novartis AG.

Spark licenses blindness gene therapy rights outside U.S. to Novartis

Jan 24 Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, has licensed rights to the drug in markets outside the United States to Switzerland-based Novartis AG, it said on Wednesday.

BRIEF-Spark Therapeutics Enters Into Licensing, Supply Agreement For Investigational Voretigene Neparvovec Outside U.S.

* SPARK THERAPEUTICS ENTERS INTO A LICENSING AND SUPPLY AGREEMENT FOR INVESTIGATIONAL VORETIGENE NEPARVOVEC OUTSIDE THE U.S.

Spark's price for Luxturna blindness gene therapy too high: ICER

The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

UPDATE 1-Spark's price for Luxturna blindness gene therapy too high -ICER

Jan 12 The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

CORRECTED-Spark's planned price for Luxturna gene therapy for rare blindness too high -ICER

Jan 12 The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

BRIEF-ICER Says Spark Therapeutics Gene Therapy Price Too High

* INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW SAYS SPARK THERAPEUTICS LUXTURNA GENE THERAPY PRICE FAR TOO HIGH

Select another date: